Strongyloidiasis: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:
==Diagnosis==
==Diagnosis==
===Symptoms===
===Symptoms===
====Gastrointestinal====
*[[Abdominal Pain]]
*[[Abdominal Pain]]
*[[Diarrhea]].  
*[[Diarrhea]].  


Pulmonary symptoms (including Loeffler’s syndrome) can occur during pulmonary migration of the filariform larvae. Dermatologic manifestations include urticarial rashes in the buttocks and waist areas.  Disseminated strongyloidiasis occurs in immunosuppressed patients, can present with [[Abdominal Pain]], Distension, [[shock]], pulmonary and neurologic complications and [[septicemia]], and is potentially fatal.
====Pulmonary====
Pulmonary symptoms (including [[Loeffler’s syndrome]]) can occur during pulmonary migration of the filariform larvae.  
 
====Skin====
Dermatologic manifestations include urticarial rashes in the buttocks and waist areas.  Disseminated strongyloidiasis occurs in immunosuppressed patients, can present with [[Abdominal Pain]], [[abdominal distension]], [[shock]], pulmonary and neurologic complications and [[septicemia]], and is potentially fatal.


===Laboratory Findings===
===Laboratory Findings===

Revision as of 01:55, 19 August 2012

WikiDoc Resources for Strongyloidiasis

Articles

Most recent articles on Strongyloidiasis

Most cited articles on Strongyloidiasis

Review articles on Strongyloidiasis

Articles on Strongyloidiasis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Strongyloidiasis

Images of Strongyloidiasis

Photos of Strongyloidiasis

Podcasts & MP3s on Strongyloidiasis

Videos on Strongyloidiasis

Evidence Based Medicine

Cochrane Collaboration on Strongyloidiasis

Bandolier on Strongyloidiasis

TRIP on Strongyloidiasis

Clinical Trials

Ongoing Trials on Strongyloidiasis at Clinical Trials.gov

Trial results on Strongyloidiasis

Clinical Trials on Strongyloidiasis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Strongyloidiasis

NICE Guidance on Strongyloidiasis

NHS PRODIGY Guidance

FDA on Strongyloidiasis

CDC on Strongyloidiasis

Books

Books on Strongyloidiasis

News

Strongyloidiasis in the news

Be alerted to news on Strongyloidiasis

News trends on Strongyloidiasis

Commentary

Blogs on Strongyloidiasis

Definitions

Definitions of Strongyloidiasis

Patient Resources / Community

Patient resources on Strongyloidiasis

Discussion groups on Strongyloidiasis

Patient Handouts on Strongyloidiasis

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis

Healthcare Provider Resources

Symptoms of Strongyloidiasis

Causes & Risk Factors for Strongyloidiasis

Diagnostic studies for Strongyloidiasis

Treatment of Strongyloidiasis

Continuing Medical Education (CME)

CME Programs on Strongyloidiasis

International

Strongyloidiasis en Espanol

Strongyloidiasis en Francais

Business

Strongyloidiasis in the Marketplace

Patents on Strongyloidiasis

Experimental / Informatics

List of terms related to Strongyloidiasis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Strongyloides Infection

Overview

Epidemiology and Demographics

Tropical and subtropical areas, but cases also occur in temperate areas (including the South of the United States). More frequently found in rural areas, institutional settings, and lower socioeconomic groups. [1]

Pathophysiology & Etiology

The nematode (roundworm) Strongyloides stercoralis. Other Strongyloides include S. fülleborni, which infects chimpanzees and baboons and may produce limited infections in humans.

Life Cycle

Life cycle of Strongyloides stercoralis

The Strongyloides life cycle is more complex than that of most nematodes with its alternation between free-living and parasitic cycles, and its potential for autoinfection and multiplication within the host. Two types of cycles exist:

Free-living cycle: The rhabditiform larvae passed in the stool 1 can either molt twice and become infective filariform larvae (direct development) 6 or molt four times and become free living adult males and females 2 that mate and produce eggs 3 from which rhabditiform larvae hatch 4 . The latter in turn can either develop 5 into a new generation of free-living adults (as represented in 2), or into infective filariform larvae 6 . The filariform larvae penetrate the human host skin to initiate the parasitic cycle 6.

Parasitic cycle: Filariform larvae in contaminated soil penetrate the human skin 6 , and are transported to the lungs where they penetrate the alveolar spaces; they are carried through the bronchial tree to the pharynx, are swallowed and then reach the small intestine 7 . In the small intestine they molt twice and become adult female worms 8 The females live threaded in the epithelium of the small intestine and by parthenogenesis produce eggs 9 , which yield rhabditiform larvae. The rhabditiform larvae can either be passed in the stool 1 (see "Free-living cycle" above), or can cause autoinfection 10 . In autoinfection, the rhabditiform larvae become infective filariform larvae, which can penetrate either the intestinal mucosa (internal autoinfection) or the skin of the perianal area (external autoinfection); in either case, the filariform larvae may follow the previously described route, being carried successively to the lungs, the bronchial tree, the pharynx, and the small intestine where they mature into adults; or they may disseminate widely in the body. To date, occurrence of autoinfection in humans with helminthic infections is recognized only in Strongyloides stercoralis and Capillaria philippinensis infections. In the case of Strongyloides, autoinfection may explain the possibility of persistent infections for many years in persons who have not been in an endemic area and of hyperinfections in immunodepressed individuals.[2]

Diagnosis

Symptoms

Gastrointestinal

Pulmonary

Pulmonary symptoms (including Loeffler’s syndrome) can occur during pulmonary migration of the filariform larvae.

Skin

Dermatologic manifestations include urticarial rashes in the buttocks and waist areas. Disseminated strongyloidiasis occurs in immunosuppressed patients, can present with Abdominal Pain, abdominal distension, shock, pulmonary and neurologic complications and septicemia, and is potentially fatal.

Laboratory Findings

Eosinophilia

Blood eosinophilia is generally present during the acute and chronic stages, but may be absent with dissemination.[3]

Stool Smaples

The diagnosis rests on the microscopic identification of larvae (rhabditiform and occasionally filariform) in the stool or duodenal fluid. Examination of serial samples may be necessary, and not always sufficient, because stool examination is relatively insensitive.

The stool can be examined in wet mounts:

  • directly
  • after concentration (formalin-ethyl acetate)
  • after recovery of the larvae by the Baermann funnel technique
  • after culture by the Harada-Mori filter paper technique
  • after culture in agar plates

The duodenal fluid can be examined using techniques such as the Enterotest string or duodenal aspiration. Larvae may be detected in sputum from patients with disseminated strongyloidiasis.

Rhabditiform larvae of Strongyloides stercoralis in wet mounts after fixation in formalin 10%. Diagnostic characteristics: length 200 to 250 µm (up to 380 µm); buccal cavity short, and prominent genital primordium.

A: Strongyloides stercoralis

A: The prominent genital primordium in the mid-section of the larva (black arrow) is readily evident. Note also the Entamoeba coli cyst (white arrow) near the posterior end of the larva.

Antibody Detection

Immunodiagnostic tests for strongyloidiasis are indicated when the infection is suspected and the organism cannot be demonstrated by duodenal aspiration, string tests, or by repeated examinations of stool. Antibody detection tests should use antigens derived from Strongyloides stercoralis filariform larvae for the highest sensitivity and specificity. Although indirect fluorescent antibody (IFA) and indirect hemagglutination (IHA) tests have been used, enzyme immunoassay (EIA) is currently recommended because of its greater sensitivity (90%). Immunocompromised persons with disseminated strongyloidiasis usually have detectable IgG antibodies despite their immunodepression. Cross-reactions in patients with filariasis and some other nematode infections may occur. Antibody test results cannot be used to differentiate between past and current infection. A positive test warrants continuing efforts to establish a parasitological diagnosis followed by antihelminthic treatment. Serologic monitoring may be useful in the follow-up of immunocompetent treated patients: antibody levels decrease markedly within 6 months after successful chemotherapy. [4]

Treatment

Pharmacotherapy

The drug of choice for the treatment of uncomplicated strongyloidiasis is ivermectin with albendazole as the alternative. All patients who are at risk of disseminated strongyloidiasis should be treated. (Albendazole is approved by the FDA, but considered investigational for this purpose).[5]

References

Template:WH Template:WS